New York State Psychiatric Institute
New York, 10032, United States
NCT Number: NCT00218114
The purpose of this study is to compare the effectiveness of divalproex sodium (Depakote) versus placebo in treating disruptive behavior disorder and explosive tempers in adolescents and adults.
Looking for future studies?
Notify Me12 year–55 year
All sexes
Interventional
Phase 3
New York, 10032, United States
Disruptive behavior disorders among children and adolescents are readily diagnosed; however, few individuals with such disorders receive drug treatment. Depakote is a mood stabilizing medication that may be beneficial in treating individuals with disruptive behavior disorders. The purpose of this study is to examine the effectiveness of Depakote in reducing temper outbursts and improving mood in individuals with disruptive behavior disorders. In addition, this study will determine the safety and effectiveness of Depakote in treating individuals with substance disorders who also have disruptive behavior disorders.
This study will last 6 weeks. Participants will be randomly assigned to receive treatment with Depakote or placebo. Medication will be given in a single evening dose if tolerated; otherwise, medication will be given twice per day. Participants will be assigned to a fixed-flexible dosing schedule and dosages will increase based on weight. All participants will attend weekly psychotherapy and family counseling sessions throughout the study. Participants who are substance abusers will also receive substance abuse counseling. Weekly study visits will include a physical exam, blood collection, and drug tests. Teachers and guidance counselors will be contacted to assess the participant's behavior from week to week. Some participants will complete a follow-up study, in which they will take part in phone interviews.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
Other names: Depakote
Participants will be on matching placebo.
Time frame: 6 weeks
Measure symptoms of disruptive behavior disorder with the modified overt aggression scale throughout the study and at Week 6
New York State Psychiatric Institute
Other
Parallel Groups Study of Divalproex Sodium (Depakote) for Irritable, Explosive Adults & Adolescents
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03698240
Attention Deficit Disorder with Hyperactivity, Attention Deficit and Disruptive Behavior Disorders
Pisa, Italy
View Trial DetailsNCT01919073
Attention Deficit Disorder with Hyperactivity, Attention Deficit Hyperactivity Disorder
Houston, Texas, United States
View Trial DetailsNCT03967509
Attention Deficit Disorder With Hyperactivity, Attention Deficit Disorder with Hyperactivity
Stockholm, Johanneshov, Sweden
View Trial DetailsNCT01940978
ADHD, Attention Deficit Disorder With Hyperactivity
Van Nuys, California, United States
View Trial Details